References
- Cantley LC . The phosphoinositide 3-kinase pathway. Science296, 1655–1657 (2002).
- Day FL , JorissenRN, LiptonLet al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin. Cancer Res.19, 3285–3296 (2013).
- Maira SM , StaufferF, BrueggenJet al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther.7, 1851–1863 (2008).
- Chan JA , BlaszkowskyL, StuartKet al. A prospective, Phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer119, 3212–3218 (2013).
- Motzer RJ , EscudierB, OudardSet al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372, 449–456 (2008).
- Janku F , WhelerJJ, WestinSNet al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol.30, 777–782 (2012).
- Moroney JW , SchlumbrechtMP, HelgasonTet al. A Phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin. Cancer Res.17, 6840–6846 (2011).
- Ganesan P , JankuF, NaingAet al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol. Cancer Ther.12, 2857–2863 (2013).
- Dienstmann R , SerpicoD, RodonJet al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in Phase I clinical trials. Mol. Cancer Ther.11, 2062–2071 (2012).
- Haagensen EJ , KyleS, BealeGS, MaxwellRJ, NewellDR. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br. J. Cancer106, 1386–1394 (2012).
- Itamochi H , OishiT, ShimadaMet al. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun. Clin. Cancer Res.17, 4742–4750 (2011).
- Liu Y , CuiB, QiaoYet al. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo. Int. J. Gynecol. Cancer21, 100–105 (2011).
- Eichhorn PJ , GiliM, ScaltritiMet al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res.68, 9221–9230 (2008).
- Brognard J , ClarkAS, NiY, DennisPA. AKT/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res.61, 3986–3997 (2001).
- ClinicalTrials.gov. www.clinicaltrials.gov
- Ihle NT , LemosRJr, WipfPet al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic RAS is a dominant predictor for resistance. Cancer Res.69, 143–150 (2009).
- Kim A , LeeJE, LeeSSet al. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int. J. Cancer133, 984–996 (2013).
- Mao C , YangZY, HuXF, ChenQ, TangJL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann. Oncol.23, 1518–1525 (2012).
- O’Reilly KE , RojoF, SheQBet al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res.66, 1500–1508 (2006).
- Rodrik-Outmezguine VS , ChandarlapatyS, PaganoNCet al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov.1, 248–259 (2011).
- Lee JT Jr , SteelmanLS, McCubreyJA. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res.64, 8397–8404 (2004).